Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro.
作者信息
Fischer K P, Tyrrell D L
机构信息
Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada.
出版信息
Antimicrob Agents Chemother. 1996 Aug;40(8):1957-60. doi: 10.1128/AAC.40.8.1957.
Abstract
Hepatitis B virus replication is very sensitive to lamivudine. A single amino acid change in human immunodeficiency virus reverse transcriptase is responsible for high-level resistance to this compound. Duck hepatitis B virus mutants were created bearing the analogous amino acid change in the duck hepatitis B virus polymerase. Viral DNA production was reduced 92% for the wild-type virus at 2 micrograms of lamivudine per ml, while the mutants required 40 micrograms of lamivudine per ml to inhibit replication by greater than 80%.
摘要
相似文献
1
Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro.
Antimicrob Agents Chemother. 1996 Aug;40(8):1957-60. doi: 10.1128/AAC.40.8.1957.
2
Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo.
J Hepatol. 2001 Jan;34(1):114-22. doi: 10.1016/s0168-8278(00)00074-x.
3
Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine.
Antimicrob Agents Chemother. 1995 Jul;39(7):1430-5. doi: 10.1128/AAC.39.7.1430.
4
Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine.
Antimicrob Agents Chemother. 1998 Dec;42(12):3179-86. doi: 10.1128/AAC.42.12.3179.
5
In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
Antimicrob Agents Chemother. 2006 Mar;50(3):955-61. doi: 10.1128/AAC.50.3.955-961.2006.
6
Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism.
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4984-9. doi: 10.1073/pnas.091324398.
7
Relationship between viral DNA synthesis and virion envelopment in hepatitis B viruses.
J Virol. 1996 Sep;70(9):6455-8. doi: 10.1128/JVI.70.9.6455-6458.1996.
8
Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.
J Virol. 2002 Feb;76(3):1213-23. doi: 10.1128/jvi.76.3.1213-1223.2002.
9
Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus.
J Gen Virol. 1999 Mar;80 ( Pt 3):601-606. doi: 10.1099/0022-1317-80-3-601.
10
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Antivir Ther. 2004 Jun;9(3):353-63.
引用本文的文献
1
Direct acting antivirals for the treatment of chronic viral hepatitis.
Scientifica (Cairo). 2012;2012:478631. doi: 10.6064/2012/478631. Epub 2012 Nov 25.
2
Humanized murine model for HBV and HCV using human induced pluripotent stem cells.
Arch Pharm Res. 2012 Feb;35(2):261-9. doi: 10.1007/s12272-012-0206-8. Epub 2012 Feb 28.
3
Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks.
Clin Vaccine Immunol. 2006 Aug;13(8):958-65. doi: 10.1128/CVI.00080-06.
4
Superinfection exclusion in duck hepatitis B virus infection is mediated by the large surface antigen.
J Virol. 2004 Aug;78(15):7925-37. doi: 10.1128/JVI.78.15.7925-7937.2004.
5
Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.
Antimicrob Agents Chemother. 2003 Jun;47(6):1936-42. doi: 10.1128/AAC.47.6.1936-1942.2003.
6
Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication.
J Virol. 2002 Jun;76(12):6356-63. doi: 10.1128/jvi.76.12.6356-6363.2002.
7
Treatment of chronic hepatitis B: new antiviral therapies.
Curr Gastroenterol Rep. 1999 Feb-Mar;1(1):20-6. doi: 10.1007/s11894-999-0082-7.
8
Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus.
J Clin Microbiol. 1999 Sep;37(9):3013-6. doi: 10.1128/JCM.37.9.3013-3016.1999.
9
Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine.
Antimicrob Agents Chemother. 1999 Aug;43(8):1947-54. doi: 10.1128/AAC.43.8.1947.
10
Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.
J Clin Invest. 1999 Jun;103(12):1635-40. doi: 10.1172/JCI5882.
本文引用的文献
1
A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives.
Antimicrob Agents Chemother. 1993 Jan;37(1):19-25. doi: 10.1128/AAC.37.1.19.
2
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Antimicrob Agents Chemother. 1993 Jan;37(1):130-3. doi: 10.1128/AAC.37.1.130.
3
Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro.
Biochem Pharmacol. 1994 Jan 20;47(2):171-4. doi: 10.1016/0006-2952(94)90002-7.
4
Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
J Med Chem. 1994 Mar 18;37(6):798-803. doi: 10.1021/jm00032a013.
5
Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro.
Antimicrob Agents Chemother. 1994 Jun;38(6):1292-7. doi: 10.1128/AAC.38.6.1292.
6
Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells.
Antimicrob Agents Chemother. 1994 Jun;38(6):1230-8. doi: 10.1128/AAC.38.6.1230.
7
Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients.
Lancet. 1995 Feb 11;345(8946):396-7. doi: 10.1016/s0140-6736(95)90388-7.
8
Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro.
Antimicrob Agents Chemother. 1994 Sep;38(9):2172-4. doi: 10.1128/AAC.38.9.2172.
9
The biochemical basis for the differential anti-human immunodeficiency virus activity of two cis enantiomers of 2',3'-dideoxy-3'-thiacytidine.
J Biol Chem. 1993 Nov 5;268(31):23234-8.
10
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653-6. doi: 10.1073/pnas.90.12.5653.
Zotero 插件